{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:17:18Z","timestamp":1790691438206,"version":"4.1.0"},"reference-count":18,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2003,6,24]],"date-time":"2003-06-24T00:00:00Z","timestamp":1056412800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2003,7]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To assess the spasmolytic effect of drotaverine hydrochloride in colicky pain caused by renal and ureteric stones.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>\n                      In a placebo\u2010controlled, multicentre, multinational, randomized, double\u2010blind study changes in the intensity of pain were recorded using a visual analogue scale (VAS), a four\u2010grade (five points) pain intensity (PI) scale and a pain\u2010relief scale. The primary endpoint was the evaluation of the antispasmodic effect of drotaverine during a 3\u2010h study period, to confirm that drotaverine abolished or significantly decreased the intensity of pain in renal colic. The painkilling effect was defined as a decrease by at least half in the PI scale, and\/or a \u2265 40% decrease in the VAS 40\u2003min after either the first or the second injection of 80\u2003mg drotaverine or placebo (if necessary the dose could be repeated once). In all, 140 patients were enrolled but 38 withdrew, leaving 102 patients for analysis (48 drotaverine, 54 placebo; mean age 42.5\u2003years,\n                      <jats:sc>sd<\/jats:sc>\n                      11.25, and 41.7,\n                      <jats:sc>sd<\/jats:sc>\n                      \u200310.79).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Drotaverine was effective in 79% of patients and placebo in only 46% (\n                      <jats:italic>P<\/jats:italic>\n                      \u2003&lt;\u20030.001). There were no serious adverse effects. There were 20 minor side\u2010effects in the drotaverine and four in the placebo group; none of the patients required treatment. The most frequent side\u2010effects were a transitory decrease in blood pressure, vertigo, nausea or vomiting.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Intravenous drotaverine provides effective pain relief in more than two\u2010thirds of patients with renal colic, with no serious side\u2010effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1046\/j.1464-410x.2003.04262.x","type":"journal-article","created":{"date-parts":[[2004,12,21]],"date-time":"2004-12-21T11:43:40Z","timestamp":1103629420000},"page":"92-96","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["The effect of drotaverine hydrochloride in acute colicky pain caused by renal and ureteric stones"],"prefix":"10.1111","volume":"92","author":[{"given":"I.","family":"Romics","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.L.","family":"Moln\u00e1r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Timberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Mrklic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Jelakovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"K\u00f6szegi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Blask\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,6,24]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"2101","volume-title":"Campbell's Urology","author":"Drach GW.","year":"1998"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1993.tb15981.x"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)38310-6"},{"key":"e_1_2_5_5_2","first-page":"203","article-title":"Egy \u00faj spasmolitikummal (NO\u2010SPA\u00ae) szerzett tapasztalatok. [Experiences obtained with a new spasmolytic drug (NO\u2010SPA\u00ae)]","volume":"13","author":"Makl\u00e1ri L.","year":"1963","journal-title":"Gy\u00f3gyszereink"},{"key":"e_1_2_5_6_2","first-page":"65","article-title":"Experience obtained with a new spasmolytic drug (NO\u2010SPA\u00ae) in the Hospital of the National Ambulance and Central Ambulance Station, Budapest","volume":"11","author":"Makl\u00e1ri L.","year":"1963","journal-title":"Therapia Hungarica"},{"key":"e_1_2_5_7_2","unstructured":"Moln\u00e1rDL.NO\u2010SPA\u00ae Az Oxiol\u00f3giai Gyakorlatban (NO\u2010SPA\u00ae in the Oxyological Practice). Budapest:Statisticalreport of SzocioMed GmbH. 1996:1\u201327"},{"key":"e_1_2_5_8_2","first-page":"454","article-title":"Vergleichende Untersuchungen \u00fcber Atropin, Papaverin und 1\u2010(3,4\u2010Dimethoxyphenyl)\u20101\u2010dimethylamino\u20104\u2010phenylbutan\u2010hydrrochlorid","volume":"6","author":"Engelhorn R","year":"1956","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(92)90045-C"},{"key":"e_1_2_5_10_2","unstructured":"KapuiZ.Summary of the specific pharmacological studies of drotaverine HCl (NO\u2010SPA). The management of smooth muscle spasm. Special monograph. Budapest:Pap \u00c1 1998:45\u201389"},{"key":"e_1_2_5_11_2","first-page":"480","article-title":"A comparative study of two antispasmodic products: buscopan and NO\u2010SPA","volume":"62","author":"Maitai CK","year":"1985","journal-title":"East African Med J"},{"key":"e_1_2_5_12_2","first-page":"2038","article-title":"Spasmolyticumok Hat\u00e1s\u00e1nak \u00d6sszehasonl\u00edt\u00f3 Klinikai M\u00e9r\u00e9se \u2013 Adatok a NO\u2010SPA\u00ae Klinikofarmakol\u00f3gi\u00e1j\u00e1hoz (Comparative studies of spasmolytics \u2013 data on the clinical pharmacology of NO\u2010SPA)","volume":"104","author":"Petr\u00e1nyi G","year":"1963","journal-title":"Orvosi Hetilap (Med Weekly)"},{"key":"e_1_2_5_13_2","first-page":"17","article-title":"The characteristics of the analgesic action of nitrosorbide and NO\u2010SPA","volume":"61","author":"Stepaniuk AG","year":"1998","journal-title":"Eksp Klin Farmakol"},{"key":"e_1_2_5_14_2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/cpt1976202241","article-title":"A model to evaluate mild analgesics in oral surgery outpatients","volume":"19","author":"Cooper SA","year":"1976","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_5_15_2","first-page":"21","article-title":"Summary of the pharmacokinetic and metabolism studies of drotaverine (NO\u2010SPA)","volume":"89","author":"Vargay Z.","year":"1989","journal-title":"Therapia Hungarica"},{"key":"e_1_2_5_16_2","first-page":"27","article-title":"Pharmacologic possibility of limiting the energy\u2010dependent accumulation of calcium by mitochondria of the ischemic myocardium","volume":"52","author":"Zamost\u2019ianova GB","year":"1989","journal-title":"Farmakol Toksikol"},{"key":"e_1_2_5_17_2","first-page":"187","article-title":"Ureterk\u00f6ves betegek kombin\u00e1lt analgetikus \u00e9s spazmolitikus kezel\u00e9s\u00e9vel el\u00e9rt eredm\u00e9nyeink (Results obtained with combined analgesic and spasmolytic treatment of patient with ureteral stone)","volume":"10","author":"Vecsey D.","year":"1983","journal-title":"Urol Nephrol Szemle"},{"key":"e_1_2_5_18_2","first-page":"456","article-title":"NO\u2010SPA\u00ae spasmolyticus hat\u00e1sa urol\u00f3giai betegeken, (The spasmolytic effect of NO\u2010SPA\u00ae on urological patients)","volume":"18","author":"Wabrosch G","year":"1968","journal-title":"Gy\u00f3gyszereink"},{"key":"e_1_2_5_19_2","first-page":"385","article-title":"Placebo \u2013 efficacy and adverse effects in controlled clinical trials","volume":"49","author":"Weibrauch TR","year":"1999","journal-title":"Artzneimittelforschung (Drug Res)"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1464-410X.2003.04262.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1464-410X.2003.04262.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:31:49Z","timestamp":1761748309000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1046\/j.1464-410X.2003.04262.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6,24]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,7]]}},"alternative-id":["10.1046\/j.1464-410X.2003.04262.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1464-410x.2003.04262.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,6,24]]},"assertion":[{"value":"2003-06-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}